Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of High Nodal Burden in Patients With Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer.
Skarping I, Bendahl PO, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Christiansen P, Filtenborg Tvedskov T, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Vrou Offersen B, Olofsson Bagge R, Reimer T, Sund M, Rydén L, de Boniface J. Skarping I, et al. Among authors: filtenborg tvedskov t. JAMA Surg. 2024 Sep 25:e243944. doi: 10.1001/jamasurg.2024.3944. Online ahead of print. JAMA Surg. 2024. PMID: 39320882 Free PMC article.
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Olofsson Bagge R, Reimer T, Sund M, Christiansen P, Rydén L, Filtenborg Tvedskov T; SENOMAC Trialists’ Group. de Boniface J, et al. Among authors: filtenborg tvedskov t. Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6. Lancet Oncol. 2024. PMID: 39121881 Clinical Trial.
Quality assessment of radiotherapy in the prospective randomized SENOMAC trial.
Alkner S, Wieslander E, Lundstedt D, Berg M, Kristensen I, Andersson Y, Bergkvist L, Frisell J, Olofsson Bagge R, Sund M, Christiansen P, Davide Gentilini O, Kontos M, Kühn T, Reimer T, Rydén L, Filtenborg Tvedskov T, Vrou Offersen B, Dahl Nissen H, de Boniface J; SENOMAC Trialists’ Group. Alkner S, et al. Among authors: filtenborg tvedskov t. Radiother Oncol. 2024 Aug;197:110372. doi: 10.1016/j.radonc.2024.110372. Epub 2024 Jun 10. Radiother Oncol. 2024. PMID: 38866204 Free article. Clinical Trial.
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists’ Group; SENOMAC Trialists' Group. de Boniface J, et al. Among authors: filtenborg tvedskov t. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. N Engl J Med. 2024. PMID: 38598571 Clinical Trial.
Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial.
Appelgren M, Sackey H, Wengström Y, Johansson K, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, Rydén L, Sund M, Alkner S, Vrou Offersen B, Filtenborg Tvedskov T, Christiansen P, de Boniface J; SENOMAC Trialists' Group. Appelgren M, et al. Among authors: filtenborg tvedskov t. Breast. 2022 Jun;63:16-23. doi: 10.1016/j.breast.2022.02.013. Epub 2022 Mar 1. Breast. 2022. PMID: 35279508 Free PMC article.
The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
de Boniface J, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, Olofsson Bagge R, Rydén L, Sund M; SENOMAC Trialists’ Group. de Boniface J, et al. Breast Cancer Res Treat. 2020 Feb;180(1):167-176. doi: 10.1007/s10549-020-05537-1. Epub 2020 Jan 27. Breast Cancer Res Treat. 2020. PMID: 31989379 Free PMC article.
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, Olofsson Bagge R, Sund M, Johansson H, Lundstedt D; SENOMAC Trialists’ Group. de Boniface J, et al. BMC Cancer. 2017 May 26;17(1):379. doi: 10.1186/s12885-017-3361-y. BMC Cancer. 2017. PMID: 28549453 Free PMC article. Clinical Trial.